Tylenol vs Abridge
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global #1 OTC acetaminophen brand owned by Kenvue (NYSE: KVUE, J&J 2023 spinoff at $41B); Kimberly-Clark $48.7B Kenvue acquisition pending close H2 2026 competing with Advil and store brand for OTC pain relief market.
About
Tylenol is a global over-the-counter acetaminophen (paracetamol) pain relief and fever reducer brand — owned by Kenvue (NYSE: KVUE), the consumer health company spun off from Johnson & Johnson in May 2023 at a $41 billion IPO valuation, and subject to a pending $48.7 billion acquisition by Kimberly-Clark announced in November 2025 (expected to close second half 2026) — providing consumers with the world's most widely used analgesic through product lines including Tylenol Extra Strength, Tylenol PM, Tylenol Rapid Release Gels, Tylenol Children's, and Tylenol Arthritis Pain for adults and pediatric pain and fever management. Generating approximately $2 billion in annual retail sales as one of Kenvue's flagship brands alongside Neutrogena, Band-Aid, Listerine, and Zyrtec, Tylenol is the #1 recommended pain reliever by doctors and pharmacists in the United States. Originally marketed by McNeil Laboratories (acquired by J&J in 1959), the brand was approved for OTC sale in 1960.
Pittsburgh ambient clinical AI (founded by cardiologist) at $5.3B valuation Jun 2025; $800M total ($300M a16z/Khosla Series E) deployed at UPMC 12K clinicians, Mayo Clinic, Johns Hopkins competing with Nuance DAX for physician documentation.
About
Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led by Andreessen Horowitz and Khosla Ventures at a $5.3 billion valuation, following a $250 million Series D just four months prior at a $2.8 billion valuation — providing physicians, nurses, and care teams at 150+ health systems with AI that automatically converts patient-clinician conversations into structured clinical notes, saving physicians an average of 3 hours daily and generating high-quality documentation from UPMC (scaling to 12,000 clinicians enterprise-wide), Mayo Clinic, Johns Hopkins, and Emory Healthcare. Abridge's AI is trained on a proprietary dataset of over 1.5 million medical encounters, delivering specialty-specific documentation through deep Epic EHR integration. Founded in 2018 by cardiologist Dr. Shiv Rao.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.